Thursday, September 5 2024
10–11am
CME/CE
Alzheimer Disease in Primary Care: Early Identification and New Anti-Amyloid Treatment Options
John A. Williams Ballroom: CDFG
Description
Timely detection of mild cognitive impairment (MCI) due to Alzheimer disease (AD) is an integral step to improving patient outcomes. This insightful session discusses early identification of MCI, clinical evaluation for an AD diagnosis, and new and emerging therapies. Gain valuable strategies to elevate detection and treatment of AD in your practice.
Learning Objectives
- Incorporate strategies that promote the early detection of mild cognitive impairment (MCI) due to Alzheimer disease (AD) into routine primary care practice
- Discuss the clinical evaluation involved in diagnosing AD, with consideration of the expanding role of biomarkers
- Examine the evidence supporting new and emerging anti-amyloid therapies, including which patient populations derive the greatest therapeutic benefit
Faculty
Educational Partner
Supported by
- This activity is supported by an educational grant from Lilly